Multilevel Factors Associated With Time to Biopsy After Abnormal Screening Mammography Results by Race and Ethnicity
- PMID: 35737381
- PMCID: PMC9227677
- DOI: 10.1001/jamaoncol.2022.1990
Multilevel Factors Associated With Time to Biopsy After Abnormal Screening Mammography Results by Race and Ethnicity
Abstract
Importance: Diagnostic delays in breast cancer detection may be associated with later-stage disease and higher anxiety, but data on multilevel factors associated with diagnostic delay are limited.
Objective: To evaluate individual-, neighborhood-, and health care-level factors associated with differences in time from abnormal screening to biopsy among racial and ethnic groups.
Design, setting, and participants: This prospective cohort study used data from women aged 40 to 79 years who had abnormal results in screening mammograms conducted in 109 imaging facilities across 6 US states between 2009 and 2019. Data were analyzed from February 21 to November 4, 2021.
Exposures: Individual-level factors included self-reported race and ethnicity, age, family history of breast cancer, breast density, previous breast biopsy, and time since last mammogram; neighborhood-level factors included geocoded education and income based on residential zip codes and rurality; and health care-level factors included mammogram modality, screening facility academic affiliation, and facility onsite biopsy service availability. Data were also assessed by examination year.
Main outcome and measures: The main outcome was unadjusted and adjusted relative risk (RR) of no biopsy within 30, 60, and 90 days using sequential log-binomial regression models. A secondary outcome was unadjusted and adjusted median time to biopsy using accelerated failure time models.
Results: A total of 45 186 women (median [IQR] age at screening, 56 [48-65] years) with 46 185 screening mammograms with abnormal results were included. Of screening mammograms with abnormal results recommended for biopsy, 15 969 (34.6%) were not resolved within 30 days, 7493 (16.2%) were not resolved within 60 days, and 5634 (12.2%) were not resolved within 90 days. Compared with White women, there was increased risk of no biopsy within 30 and 60 days for Asian (30 days: RR, 1.66; 95% CI, 1.31-2.10; 60 days: RR, 1.58; 95% CI, 1.15-2.18), Black (30 days: RR, 1.52; 95% CI, 1.30-1.78; 60 days: 1.39; 95% CI, 1.22-1.60), and Hispanic (30 days: RR, 1.50; 95% CI, 1.24-1.81; 60 days: 1.38; 95% CI, 1.11-1.71) women; however, the unadjusted risk of no biopsy within 90 days only persisted significantly for Black women (RR, 1.28; 95% CI, 1.11-1.47). Sequential adjustment for selected individual-, neighborhood-, and health care-level factors, exclusive of screening facility, did not substantially change the risk of no biopsy within 90 days for Black women (RR, 1.27; 95% CI, 1.12-1.44). After additionally adjusting for screening facility, the increased risk for Black women persisted but showed a modest decrease (RR, 1.20; 95% CI, 1.08-1.34).
Conclusions and relevance: In this cohort study involving a diverse cohort of US women recommended for biopsy after abnormal results on screening mammography, Black women were the most likely to experience delays to diagnostic resolution after adjusting for multilevel factors. These results suggest that adjustment for multilevel factors did not entirely account for differences in time to breast biopsy, but unmeasured factors, such as systemic racism and other health care system factors, may impact timely diagnosis.
Conflict of interest statement
Figures
Comment in
-
Addressing Racial and Ethnic Differences in Diagnostic Resolution of Abnormal Mammographic Findings.JAMA Oncol. 2022 Aug 1;8(8):1126-1127. doi: 10.1001/jamaoncol.2022.1864. JAMA Oncol. 2022. PMID: 35737428 No abstract available.
-
Beyond the AJR: Racial and Ethnic Disparities in the Timeliness of Biopsy After Abnormal Screening Mammography.AJR Am J Roentgenol. 2023 May;220(5):762. doi: 10.2214/AJR.22.28458. Epub 2022 Sep 7. AJR Am J Roentgenol. 2023. PMID: 36069485 No abstract available.
Similar articles
-
Diagnostic Mammography Performance across Racial and Ethnic Groups in a National Network of Community-Based Breast Imaging Facilities.Cancer Epidemiol Biomarkers Prev. 2022 Jul 1;31(7):1324-1333. doi: 10.1158/1055-9965.EPI-21-1379. Cancer Epidemiol Biomarkers Prev. 2022. PMID: 35712862 Free PMC article.
-
Characterizing participants in the North Carolina Breast and Cervical Cancer Control Program: A retrospective review of 90,000 women.Cancer. 2021 Jul 15;127(14):2515-2524. doi: 10.1002/cncr.33473. Epub 2021 Apr 7. Cancer. 2021. PMID: 33826758 Free PMC article. Review.
-
Assessment of a Risk-Based Approach for Triaging Mammography Examinations During Periods of Reduced Capacity.JAMA Netw Open. 2021 Mar 1;4(3):e211974. doi: 10.1001/jamanetworkopen.2021.1974. JAMA Netw Open. 2021. PMID: 33764423 Free PMC article.
-
Comparative Access to and Use of Digital Breast Tomosynthesis Screening by Women's Race/Ethnicity and Socioeconomic Status.JAMA Netw Open. 2021 Feb 1;4(2):e2037546. doi: 10.1001/jamanetworkopen.2020.37546. JAMA Netw Open. 2021. PMID: 33606032 Free PMC article.
-
Benefits and Harms of Breast Cancer Screening: A Systematic Review.JAMA. 2015 Oct 20;314(15):1615-34. doi: 10.1001/jama.2015.13183. JAMA. 2015. PMID: 26501537 Review.
Cited by
-
Minorities Face Delays to Pancreatic Cancer Treatment Regardless of Diagnosis Setting.Ann Surg Oncol. 2024 May 24. doi: 10.1245/s10434-024-15352-3. Online ahead of print. Ann Surg Oncol. 2024. PMID: 38789617
-
Multilevel contributors to racial and ethnic inequities in the resolution of abnormal mammography results.Cancer Causes Control. 2024 Jul;35(7):995-1009. doi: 10.1007/s10552-024-01851-x. Epub 2024 Mar 13. Cancer Causes Control. 2024. PMID: 38478206
-
Understanding mechanisms of racial disparities in breast cancer: an assessment of screening and regular care in the Carolina Breast Cancer Study.Cancer Causes Control. 2024 May;35(5):825-837. doi: 10.1007/s10552-023-01833-5. Epub 2024 Jan 13. Cancer Causes Control. 2024. PMID: 38217760
-
Validating racial and ethnic non-bias of artificial intelligence decision support for diagnostic breast ultrasound evaluation.J Med Imaging (Bellingham). 2023 Nov;10(6):061108. doi: 10.1117/1.JMI.10.6.061108. Epub 2023 Dec 12. J Med Imaging (Bellingham). 2023. PMID: 38106815
-
Racial Disparities in Breast Cancer: from Detection to Treatment.Curr Oncol Rep. 2024 Jan;26(1):10-20. doi: 10.1007/s11912-023-01472-8. Epub 2023 Dec 15. Curr Oncol Rep. 2024. PMID: 38100011 Review.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical